Glycylproline dipeptidyl aminopeptidase isoenzyme in diagnosis of primary hepatocellular carcinoma

World Journal of Gastroenterology

Volumn 9, Issue 4, 2003, Pages 710-713

  Ni, Run Zhou ^a   Huang, Jie Fei ^a   Xiao, Ming Bing ^a   Li, Mei ^a   Meng, Xian Yong ^a  

^a NANTONG MEDICAL COLLEGE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; BIOLOGICAL MARKER; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV F; DIPEPTIDYL PEPTIDASE IV S; GLYCOPROTEIN; ISOENZYME; POLYACRYLAMIDE; SIALIC ACID; SIALIDASE; UNCLASSIFIED DRUG;

ARTICLE; CHRONIC HEPATITIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DRUG EFFECT; ENZYME BLOOD LEVEL; ENZYME REGULATION; GEL ELECTROPHORESIS; HUMAN; LIVER ABSCESS; LIVER CANCER; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER CYST; LIVER DISEASE; LIVER HEMANGIOMA; LIVER METASTASIS; MAJOR CLINICAL STUDY; TUMOR VOLUME;

EID: 0037624728     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v9.i4.710     Document Type: Article

References (36)

1. Hopsu-Havu VK, Glenner GG. A new dipeptide naphthylamidase hydrolyzing glycyl-prolyl-beta-naphthlamide. Histochemie 1966; 7: 197-201
2. Hutchinson DR, Halliwell RP, Lockhart JD, Parke DV. Glycylprolyl-p-nitroanilidase in hepatobiliary disease. Clin Chem Acta 1981; 109: 83-89
3. Kojima J, Kanatani M, Nakamura N, Kashiwagi T, Tohjoh F, Akiyama M. Serum and liver glycylproline dipeptidyl aminopeptidase activity in rats with experimental hepatic cancer. Clin Chem Acta 1980; 107: 105-110
4. Kojima J, Ueno Y, Kasugai H, Okuda S, Akedo H. Glycylproline dipepdidyl aminopeptidase and gamma-glutamyl transpeptidase in human hepatic cancer and embryonal tissues. Clin Chem Acta 1987; 167: 285-291
5. Bergmeyer HU, Horder M, Rej R. International federation of clinical chemistry (IFCC) scientific committee, analytical section: Approved recommendation (1985) on IFCC methods for the measurement of catalytic concentration of enzymes. Part 3. IFCC method for alanine aminotransferase (L-alanine: 2-oxoglutarate aminotransferase, EC 2.6.1.2). J Clin Chem Clin Biochem 1986; 24: 481-495
6. Tang ZY. Hepatocellular carcinoma-cause, treatment and metastasis. World J Gastroenterol 2001; 7: 445-454
7. Tang ZY. Hepatocellular carcinoma. J Gastroenterol Hepatol 2000; 15 (Suppl): G1-7
8. Rabe C, Pilz T, Klostermann C, Berna M, Schild HH, Sauerbruch T, Caselmann WH. Clinical characteristics and outcome of a cohort of 101 patients with hepatocellular carcinoma. World J Gastroenterol 2001; 7: 208-215
9. Tangkijvanich P, Anukulkarnkusol N, Suwangool P, Lertmaharit S, Hanvivatvong O, Kullavanijaya P, Poovorawa Y. Clinical characteristics and prognosis of hepatocellular carcinoma: Analysis based on serum alpha-fetoprotein levels. J Clin Gastroenterol 2000; 31: 302-308
10. Yoshida S, Kurokohchi K, Arima K, Masaki T, Hosomi N, Funaki T, Murota M, Kita Y, Watanabe S, Kuriyama S. Clinical significance of lens culinaris agglutini-reactive fraction of serum alpha-fetoprotein in patients with hepatocellular carcinoma. Int J Oncol 2002; 20: 305-309
11. Qin LX, Tang ZY. The prognostic significance of clinical and pathologica 1 features in hepatocellular carcinoma. World J Gastroenterol 2002; 8: 193-199
12. Tamura A, Oita T, Sakizono K, Nakajima T, Kasakura S. Clinical usefulness of lectin-reactive fraction of alpha-fetoprotein in hepatocellular carcinoma. Rinsho Byori 1998; 46: 158-162
13. Zaninotto M, Ujka F, Lachin M, Bernardi D, Marafi C, Farinati F, Plebani M. Lectini-affinity electrophoresis for the detection of AFP microheterogeneities in patients with hepatocellular carcinoma. Anticancer Res 1996; 16: 305-309
14. Kumada T, Nakano S, Takeda I, Kiriyama S, Sone Y, Hayashi K, Katoh H, Endoh T, Sassa T, Satomura S. Clinical utility of Lens culinaris agglutinin-reactive alpha-fetoprotein in small hepatocellular carcinoma: Special reference to imaging diagnosis. J Hepatol 1999; 30: 125-130
15. Hayashi K, Kumada T, Nakano S, Takeda I, Sugiyama K, Kiriyama S, Sone Y, Miyata A, Shimizu H, Satomura S. Usefulness of measurement of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein as a marker of prognosis and recurrence of small hepatocellular carcinoma. Am J Gastroenterol 1999; 94: 3028-3033
16. Li D, Mallory T, Satomura S. AFP-L3: A new generation of tumor marker for hepatocellular carcinoma. Clin Chim Acta 2001; 313: 15-19
17. Sakon M, Monden M, Gotoh M, Kanai T, Umeshita K, Nakano Y, Mori T, Sakurai M, Wakasa K. Relationship between pathologic prognostic factors and abnormal levels of des-gamma-carboxy prothrombin and alpha-fetoprotein in hepatocellular carcinoma. Am J Surg 1992; 163: 251-256
18. Lamerz R, Runge M, Stieber P, Meissner E. Use of serum PIVKA-II (DCP) determination for differentiation between benign and malignant liver diseases. Anticancer Res 1999; 19: 2489-2493
19. Tanaka Y, Kashiwagi T, Tsutsumi H, Nagasawa M, Toyama T, Ozaki S, Naito M, Ishibashi K, Azuma M. Sensitive measurement of serum abnormal prothrombin (PIVKA-II) as a marker of hepatocellular carcinoma. Hepatogastroenterogy 1999; 46: 2464-2468
20. Sassa T, Kumada T, Nakano S, Uematsu T. Clinical utility of simultaneous measurement of serum high-sensitivity desgamma-carboxy prothrombin and lens culinaris agglutinit A-reactive alpha-fetoprotein in patients with small hepatocellular carcinoma. Eur J Gastroenterol Hepatol 1999; 11: 1387-1392
21. Ishii M, Gama H, Chida N, Ueno Y, Shinzawa H, Takagi T, Toyota T, Takahashi T, Kasukawa R. Simultaneous measurements of serum alpha-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma. South tohoku district study group. Am J Gastroenterol 2000; 95: 1036-1040
22. Ikoma J, Kaito M, Ishihara T, Nakagawa N, Kamei A, Fujita N, Iwasa M, Tamaki S, Watanabe S, Adachi Y. Early diagnosis of hepatocellular carcinoma using sensitive assay for serum des-gamma-carboxy prothrombin: A prospective study. Hepatogastroenterology 2002; 49: 235-238
23. Fujiyama S, Tanaka M, Maeda S, Ashihara H, Hirata R, Tomita K. Tumor markers in early diagnosis, follow-up and management of patients with hepatocellular carcinoma. Oncology 2002; 62(Suppl 1): 57-63
24. Okuyama K. Separation and identification of serum gamma-glutamyl transpeptidase isoenzymes by wheat germ agglutinin affinity electrophoresis: A basic analysis and its clinical application to various liver diseases. Keio J Med 1993; 42: 149-156
25. Sacchetti L, Castaldo G, Cimino L, Budillon G, Salvatore F. Diagnostic efficiency in discriminating liver malignancies from cirrhosis by serum gamma-glutamyl transferase isoforms. Clin Chim Acta 1988; 177: 167-172
26. Xu K, Meng XY, Wu JW, Shen B, Shi B, Shi YC, Wei Q. Diagnostic value of serum gamma-glutamyl transferase isoenzyme for hepatocellular carcinoma: A 10-year study. Am J Gastroenterol 1992; 87: 991-995
27. Tsai JF, Chuang LY, Jeng JE, Yang ML, Chang WY, Hsieh MY, Lin ZY, Tsai JH. Clinical relevance of transforming growth factor-beta 1 in the urine of patients with hepatocellular carcinoma. Medicine 1997; 76: 213-226
28. Sacco R, Leuci D, Tortorella C, Fiore G, Marinosci F, Schiraldi O, Antonaci S. Transforming growth factor beta1 and soluble Fas serum levels in hepatocellular carcinoma. Cytokine 2000; 12: 811-814
29. Song BC, Chung YH, Kim JA, Choi WB, Suh DD, Pyo SI, Shin JW, Lee HC, Lee YS, Suh DJ. Transforming growth factor-beta 1 as a useful serological marker of small hepatocellular carcinoma. Cancer 2002; 94: 175-180
30. Giardina MG, Matarazzo M, Varriale A, Morante R, Napoli A, Martino R. Serum alpha-L-fucosidase. A useful marker in the diagnosis of hepatocellular carcinoma. Cancer 1992; 70: 1044-1048
31. Takahashi H, Saibara T, Iwamura S, Tomita A, Maeda T, Onishi S, Yamamoto Y, Enzan H. Serum alpha-L-fucosidase activity and tumor size in hepatocellular carcinoma. Hepatology 1994; 19: 1414-1417
32. Giardina MG, Matarazzo M, Morante R, Lucariello A, Varriale A, Guardasole V, De Marco G. Serum alpha-L-fucosidase activity and early detection of hepatocellular carcinoma: A prospective study of patients with cirrhosis. Cancer 1998; 83: 2468-2474
33. Ishizuka H, Nakayama T, Matsuoka S, Goth I, Ogawa M, Suzuki K, Tanaka N, Tsubaki K, Ohkubo H, Arakawa Y, Okano T. Prediction of the development of hepato-cellular-carcinoma in patients with liver cirrhosis by the serial determinations of serum alpha-L-fucosidase activity. Intern Med 1999; 38: 927-931
34. Tangkijvanich P, Tosukhowong P, Bunyongyod P, Lertmaharit S, Hanvivatvong O, Kullavanijaya P, Poovorawan Y. Alpha-L-fucosidase as a serum marker of hepatocellular carcinoma in Thailand. Southeast Asian J Trop Med Public Health 1999; 30: 110-114
35. Naitoh A, Aoyagi Y, Asakura H. Highly enhanced fucosylation of serum glycoprotein in patients with hepatocellular carcinoma. J Gastroenterol Hepatol 1999; 14: 436-445
36. Mita Y, Aoyagi Y, Suda T, Asakura H. Plasma fucosyltransferase activity in patients with hepatocellular carcinoma, with special reference to correlation with fucosylated species of alpha-fetoprotein. J Hepatol 2000; 32: 946-954